viewCanntab Therapeutics Ltd

Canntab Therapeutics inks pact with Heritage Cannabis for processing hemp for CBD-filled gelcaps

Heritage's subsidiary Purefarma Solutions will take hemp from Canntab for the purpose of processing it into high-quality CBD oil

CBD gelcaps
Canntab is best known for its tablet technology, which includes an extended-release, instant-release, flash melt tablet and more

Canntab Therapeutics Limited (CSE:PILL.CN) (OTCMKTS:CTABF) said Thursday that it has inked a pact with Heritage Cannabis Holdings Corp (CSE:CANN)(OTCQX:HERTF) for processing hemp for sale of CBD filled gel capsules.

Canntab has a Health Canada license to cultivate industrial hemp that it uses to extract cannabidiol (CBD) to manufacture cannabis pills.

According to the term sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions for the purpose of processing that hemp into high quality CBD oil.

READ: Canntab Therapeutics fills a gap with its pioneering cannabis oral dosage products

The oil will then be turned into capsules by Canntab for Heritage, FSD Pharma Inc (CSE:HUGE), and other white labelling opportunities.

The agreement will begin immediately and is open-ended, non-exclusive and subject to a 120-day cancellation notice by either party.

Strategic deal to spur growth 

“This agreement with Canntab is a strategic fit for our growth as a contract service provider. It aligns with our vision to operate in final product verticals and advances our offering in the medical cannabis sector,” said Heritage Cannabis Holdings CEO Clint Sharples. “Purefarma’s extraction expertise and ability to provide quality oil is a good match for the high expectations that Canntab has for the products they will be bringing to market.”

Canntab's oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract.

"After recently announcing the receipt of our cultivation licence for industrial hemp from Health Canada, we are immediately entering into important agreements to generate both short term and sustained revenue for the company,” said Canntab co-founder and CEO Jeff Renwick. “Our ability to encapsulate allows us to generate revenue without losing our long term focus on becoming the leading supplier of hard pill oral dose cannabinoid and terpene blends in the world."

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter@UttaraProactive 

Quick facts: Canntab Therapeutics Ltd

Price: 0.74 CAD

Market: CSE
Market Cap: $23.29 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...


Canntab Therapeutics achieves major milestone receiving first U.S. patent...

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CEO Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has secured protection for their intellectual property receiving a U.S. patent for “Modified Release Multi-Layer Tablet Cannabinoid Formulations.” Latowsky...

1 day, 8 hours ago

2 min read